1 / 26

FibroMax in the most common liver diseases

FibroMax in the most common liver diseases. FibroMax: a universal biomarker of liver disease. In this Presentation. FibroMax. SteatoTest. FibroTest. NashTest. ActiTest. AshTest. For NASH activity. For Viral activity. For ASH activity. For Fibrosis. For Steatosis. What is FibroMax?.

thisbe
Download Presentation

FibroMax in the most common liver diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FibroMax in the most common liver diseases FibroMax: a universal biomarker of liver disease FT in diagnostic of HBV

  2. In this Presentation FT in diagnostic of HBV

  3. FibroMax SteatoTest FibroTest NashTest ActiTest AshTest For NASH activity For Viral activity For ASH activity For Fibrosis For Steatosis What is FibroMax? • 5 tests together to assess liver injuries in HBV, HCV, NAFLD, ALD FT in diagnostic of HBV

  4. FibroMax in Viral Hepatitis FibroTest-ActiTest presentation FT in diagnostic of HBV

  5. FibroMax SteatoTest FibroTest NashTest ActiTest AshTest For NASH activity For Viral activity For ASH activity For Fibrosis For Steatosis FT in diagnostic of HBV

  6. FibroMax in viral hepatitis B and C • For more information please report to following presentations • FibroTest in the diagnosis of HBV, FibroTest: prognostic value in HBV , FibroTest in the diagnosis of HCV, FibroTest: prognostic value in HCV Presentations available on www.oneliver.com • Relationship between FibroTest and the stage of firbosis and between ActiTest and the grade of Activity FT in diagnostic of HBV

  7. FibroMax in Steatosis SteatoTest Presentation FT in diagnostic of HBV

  8. FibroMax SteatoTest FibroTest NashTest ActiTest AshTest For NASH activity For Viral activity For ASH activity For Fibrosis For Steatosis FT in diagnostic of HBV

  9. Population at risk of liver steatosis (Millions) FT in diagnostic of HBV Bellentani, Dionysos Study, J Hepatol 2001

  10. Biomarker activity in steatosis FibroTest FibroMax Alpha2Macroglobulin ALT Total Bilirubin AST Gamma GT Triglycerides Apolipoprotein A1 Cholesterol Haptoglobin Glucose FT in diagnostic of HBV + Weight, Height + Age, Gender

  11. Poynard Comp Hepatol 2005 • The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis FT in diagnostic of HBV

  12. SteatoTest versus GGT and ALTPoynard Comp Hepatol 2005 • Relationship between ST, GGT and ALT and the grade of liver steatosis in the 3 validation groups FT in diagnostic of HBV

  13. SteatoTest versus GGT and ALTPoynard Comp Hepatol 2005 • Relationship between ST, GGT and ALT and the grade of liver steatosis in the integrated database combining controls, training group and validation groups FT in diagnostic of HBV

  14. SteatoTest versus UltraSonographyPoynard et al, Comp Hepato 2005 • Biopsy as Gold Standard n=304 FT in diagnostic of HBV

  15. FibroMax in Non Alcoholic Steato-Hepatitis NashTest FT in diagnostic of HBV

  16. FibroMax SteatoTest FibroTest NashTest ActiTest AshTest For NASH activity For Viral activity For ASH activity For Fibrosis For Steatosis FT in diagnostic of HBV

  17. NashTest: AUROCPoynard et al, BMC Gastro 2006 • AUROC NASH = 0.83 (SE=0.04) -- Nash -- Borderline Nash -- No Nash FT in diagnostic of HBV

  18. NashTest versus Biopsy- Poynard et al BMC Gastro 2006 • Concordance between NASH predicted by NashTest and predicted by biopsy (in all patients n=257) FT in diagnostic of HBV

  19. NashTest versus Biopsy- Poynard et al BMC Gastro 2006 • Sensitivity, Specificity and predictive values of NashTest for the diagnosis of NASH (in all patients n=257) Conclusion • In patients with non-alcoholic fatty liver disease, NashTest, a simple and non-invasive biomarker reliably predicts the presence or absence of NASH. • Among patients with NAFLD, the new generation of biomarkers such as FibroTest, SteatoTest and NashTest will allow better identification of those at risk and reassurance for patients without fibrosis or NASH. • Biomarkers as a first-line estimate of injury in chronic liver diseases should reduce the need for liver biopsy FT in diagnostic of HBV

  20. Proposed screening strategy of advanced fibrosis, steatosis and NASH in NAFLD patients. FT in diagnostic of HBV

  21. FibroMax in Alcoholic Steato-Hepatitis AshTest FT in diagnostic of HBV

  22. FibroMax SteatoTest FibroTest NashTest ActiTest AshTest For NASH activity For Viral activity For ASH activity For Fibrosis For Steatosis FT in diagnostic of HBV

  23. AshTest versus AST/ALT and MaddreyThabut et al, J Hepatol 2006 FT in diagnostic of HBV

  24. AshTest versus AST/ALT and MaddreyThabut et al, J Hepatol 2006 • ROC curves of AshTest, Maddrey and AST/ALT ratio for the diagnosis of alcoholic hepatitis (n=225). Conclusions AshTest AST/ALT Maddrey FT in diagnostic of HBV

  25. Proposed screening strategy of severe alcoholic steatohepatitis (ASH) in excessive drinkers • ASH screening and treatment strategy FT in diagnostic of HBV

  26. Proposed screening strategy of severe alcoholic steatohepatitis (ASH) in excessive drinkers • Fibrosis screening strategy in ALD patient FT in diagnostic of HBV

More Related